Global Coronavirus Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Coronavirus Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Coronavirus Vaccine is an innovative vaccine to prevent and control diseases caused by novel coronavirus infection. At present, there are many types of Coronavirus Vaccine on the market, and different types of research and development approaches are different.

Market Overview:

The latest research study on the global Coronavirus Vaccine market finds that the global Coronavirus Vaccine market reached a value of USD 73423.7 million in 2022. It’s expected that the market will achieve USD 4316.89 million by 2028, exhibiting a CAGR of -37.64% during the forecast period.

Downstream demand is huge

COVID-19 virus is a highly contagious virus. Since the first outbreak of COVID-19 in China in 2019, more than 500 million people around the world have been infected with the COVID-19 virus, and more than 6 million people have died from it. After that, with the efforts of researchers all over the world, a variety of Coronavirus vaccines have been developed and put into use. According to several infectious disease experts, more than 70% of the world's population needs to be vaccinated in order to obtain a safe environment for COVID-19.

As of July 21, 2022, more than 5.2 billion people around the world have been vaccinated with a dose of the Coronavirus Vaccine, and more than 4.8 billion of them have been completely vaccinated with Coronavirus Vaccine. Although more than half of the people in the world have been vaccinated with Coronavirus Vaccine, some vaccines have a limited time to immunize the human body, and regular injections are needed to achieve a lasting immunization effect. COVID-19 will continue to exist in the next few years, so there will still be a huge demand for Coronavirus vaccines in the world in the next few years. The huge global demand for Coronavirus vaccines has brought opportunities for the development of the industry.

High R&D expenditure

The research and development of the Coronavirus Vaccine is a huge capital-intensive process. The storage and distribution cost of vaccines is higher than that of any other drug because it requires monitoring equipment and special equipment. The lack of proper storage and distribution facilities will reduce the efficiency and quality of vaccines. The development process of the Coronavirus Vaccine needs to invest hundreds of millions of dollars. In addition, because of the low success rate of vaccine development, manufacturers find it challenging to manage operating costs and obtain initial investment. The high cost of vaccine development and storage is inhibiting the growth of the Coronavirus Vaccine market. Many investors tend to avoid this kind of investment project with uncertain returns. This has brought great challenges to the development of the Coronavirus Vaccine market. In addition, with the emergence of new variants, the R&D of Coronavirus vaccines needs to be constantly updated, which requires continuous funding for the research of new vaccines, which will also bring great challenges to investors.

Region Overview:

Geographically, Asia Pacific held the largest market share – 42.44% in 2022.

Company Overview:

Pfizer is one of the major players operating in the Coronavirus Vaccine market, holding a share of 34.78% in 2022.

Pfizer

Pfizer is a leading research biopharmaceutical company. Pfizer develops and produces drugs and vaccines for immunology, oncology, cardiology, endocrinology and neurology. The company owns several heavy drugs or products. Pfizer has developed and launched a variety of products for COVID-19 pandemic, including Pfizer -BioNTech COVID-19 vaccine and Paxlovid.

China National Pharmaceutical Group Corp

China National Pharmaceutical Group Corp was established in 1964, and its business covers a series of business activities from production and operation to investment services. China National Pharmaceutical Group Corp takes the pharmaceutical industry chain and narcotics business as its core business, and has built production bases and medicinal materials bases for biological drugs, narcotic drugs and psychotropic drugs, anti-infective drugs, tumor drugs, cardiovascular drugs and respiratory drugs. Some production lines have been approved by FDA and EU authorities, and have passed the prequalification of WHO.

Segmentation Overview:

Among different product types, Coronavirus Vaccine Based on S Protein segment is anticipated to contribute the largest market share in 2028.

Coronavirus Inactivated Vaccine

Coronavirus Inactivated Vaccine is a vaccine prepared by killing pathogenic microorganisms while retaining the immunogenicity of the corresponding antigen. Inactivated virus is used to stimulate immune response. Coronavirus Inactivated Vaccine inactivated the live virus and inoculated it to human body as antigen. The composition of this vaccine is closest to the natural virus structure.

Live Attenuated Coronavirus Vaccine

Live Attended coronavirus vaccine is a pathogen variant with reduced toxicity or no toxicity after genetic modification or chemical treatment of live virus. Inoculated to human body, it still has the ability to induce an antiviral immune response similar to that of naturally infected viruses. Generally, this vaccine can induce both antibody immunity and cellular immunity.

Coronavirus Vaccine Based on S Protein

This kind of vaccine uses RNA or DNA containing S protein replication instruction after genetic engineering treatment. These replicas promote the immune response of human body against coronavirus.

Application Overview:

In the Coronavirus Vaccine market, 54.27% of the total value was generated through the Hospital segment by application in 2022.

Key Companies in the global Coronavirus Vaccine market covered in Chapter 3:

China National Pharmaceutical Group Corp
Nоvаvах
Pfizer
Sinovac Biotech
Modеrnа
Bharat Biotech
CanSino Biologics Inc
AstraZeneca
Chongqing Zhifei Biological Products Co., Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the Coronavirus Vaccine market from 2018 to 2029 is primarily split into:

Coronavirus Inactivated Vaccine
Live Attenuated Coronavirus Vaccine
Coronavirus Vaccine Based on S Protein

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Coronavirus Vaccine market from 2018 to 2029 covers:

Hospital
Clinic
Research Institute
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)